Fisher Asset Management LLC Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fisher Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,338,062 shares of the biotechnology company's stock after acquiring an additional 481,359 shares during the quarter. Fisher Asset Management LLC owned 1.61% of BioCryst Pharmaceuticals worth $25,369,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BCRX. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Xponance Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 1,505 shares in the last quarter. Creative Planning grew its position in shares of BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock valued at $375,000 after acquiring an additional 2,734 shares during the period. CWM LLC increased its stake in shares of BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Finally, Diversified Trust Co raised its holdings in BioCryst Pharmaceuticals by 18.0% in the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 3,774 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.01 during mid-day trading on Thursday, hitting $7.50. 1,056,322 shares of the stock were exchanged, compared to its average volume of 2,912,146. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.29 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $8.88. The stock's fifty day simple moving average is $7.62 and its two-hundred day simple moving average is $7.28.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals's quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.19) EPS. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BCRX shares. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Finally, JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.